The effect of twice-daily aclidinium bromide on cough and sputum in patients with COPD: Results from phase III studies

被引：0
|
作者：
McGarvey, Lorcan
Morice, Alyn
Smith, Jacky
Birring, Surinder
Chuecos, Ferrari
Seoane, Beatriz
Jarreta, Diana
机构：
来源：
EUROPEAN RESPIRATORY JOURNAL | 2014年 / 44卷
关键词：
Bronchodilators; COPD; -; management; Cough;
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Twice-Daily Aclidinium Bromide/formoterol Fumarate Fixed-Dose Combination: Lung Function Improvements In The Augment COPD Trial In Patients With Moderate To Severe COPD
    D'Urzo, A. D.
    Rennard, S. I.
    Kerwin, E. M.
    Mergel, V.
    Leselbaum, A.
    Caracta, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [22] Dose-Ranging Study of 2 Fixed-Dose Combinations of Twice-Daily Aclidinium Bromide Plus Formoterol in Patients With Moderate to Severe COPD
    Kerwin, Edward
    Lapidus, Robert
    Leselbaum, Anne
    Ortiz, Stephan
    Rowe, Paul
    Caracta, Cynthia
    CHEST, 2013, 144 (04)
  • [23] Efficacy of Aclidinium Bromide 400 μg Twice Daily Compared With Placebo and Tiotropium in Patients With Moderate to Severe COPD
    Fuhr, Rainard
    Magnussen, Helgo
    Sarem, Kristina
    Ribera Llovera, Anna
    Kirsten, Anne-Marie
    Falques, Meritxell
    Caracta, Cynthia F.
    Garcia Gil, Esther
    CHEST, 2012, 141 (03) : 745 - 752
  • [24] Lung function improvements with twice-daily aclidinium/formoterol fixed-dose combination in two 24-week studies in patients with COPD
    Singh, Dave
    D'Urzo, Anthony
    Jones, Paul
    Serra, Cristina
    Mergel, Victor
    Caracta, Cynthia
    Leselbaum, Anne
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [25] ACCORD COPD II: A Randomized Clinical Trial to Evaluate the 12-Week Efficacy and Safety of Twice-Daily Aclidinium Bromide in Chronic Obstructive Pulmonary Disease Patients
    Stephen I. Rennard
    Paul D. Scanlon
    Gary T. Ferguson
    Ludmyla Rekeda
    Brian T. Maurer
    Esther Garcia Gil
    Cynthia F. Caracta
    Clinical Drug Investigation, 2013, 33 : 893 - 904
  • [26] ACCORD COPD II: A Randomized Clinical Trial to Evaluate the 12-Week Efficacy and Safety of Twice-Daily Aclidinium Bromide in Chronic Obstructive Pulmonary Disease Patients
    Rennard, Stephen I.
    Scanlon, Paul D.
    Ferguson, Gary T.
    Rekeda, Ludmyla
    Maurer, Brian T.
    Garcia Gil, Esther
    Caracta, Cynthia F.
    CLINICAL DRUG INVESTIGATION, 2013, 33 (12) : 893 - 904
  • [27] Effect of aclidinium bromide on dyspnoea and health status in patients with stable COPD: Phase III data by GOLD 2013 classification
    Mroz, Robert M.
    Ausin, Maria Pilar
    Lamarca, Rosa
    Gil, Esther Garcia
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [28] Effect of Aclidinium Bromide on Exacerbations in Patients with Moderate-to-Severe COPD: A Pooled Analysis of Five Phase III, Randomized, Placebo-Controlled Studies
    Wedzicha, Jadwiga A.
    Agusti, Alvar
    Donaldson, Gavin
    Chuecos, Ferran
    Lamarca, Rosa
    Gil, Esther Garcia
    COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2016, 13 (06) : 669 - 676
  • [29] A Phase III Study Evaluating Aclidinium Bromide, a Novel Long-Acting Antimuscarinic, in Patients with COPD: ACCLAIM/COPD I
    Jones, P. W.
    Agusti, A.
    Chanez, P.
    Magnussen, H.
    Fabbri, L.
    Maroni, J.
    Garcia-Gil, E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [30] A PHASE III STUDY EVALUATING ACLIDINIUM BROMIDE, A NOVEL LONG-ACTING ANTIMUSCARINIC, IN PATIENTS WITH COPD: ACCLAIM/COPD I
    Jones, P. W.
    Chanez, P.
    Agusti, A.
    Magnussen, H.
    Fabbri, L.
    Caracta, C.
    Garcia Gil, E.
    THORAX, 2009, 64 : A168 - A168
12345